报价延迟最少15分钟:2026/01/07 14:05 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.6731 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.66/-0.33
|
|
企业价值
17.52M
|
| 资产负债 |
|
每股账面净值
0.12
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
705.92K
|
|
每股收益
0.01
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology. |
